INCYTE CORP (INCY) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$127.67

From 52W high−3.56%

Volume3.66M

Market cap$25.40B

P/E (TTM)15.4x

P/S (TTM)4.4x

Div yield—

Key dataSep 18, 2026

Open

$127.67

From 52W high

−3.56%

Volume

3.66M

Market cap

$25.40B

ValuationView details →

P/E (Fwd)

43.3x

EV/EBITDA

10.2x

P/E (TTM)

15.4x

RSI (14)

57.5

MomentumView details →

1D Return

−1.81%

YTD Return

+29.13%

SummaryUpdated Jun 1, 2026

Incyte Corporation (NASDAQ:INCY) is a biopharmaceutical company founded in 1991 and headquartered in Wilmington, Delaware. The company went public in 1993 and has evolved from a genomics research company into a fully integrated biopharmaceutical enterprise focused on discovering, developing, and commercializing innovative therapeutics. Incyte operates primarily in the United States and internationally, with a strong presence in oncology, hematology, and dermatology markets. The company has successfully transitioned from a research-focused organization to one with multiple marketed products generating substantial revenue, while maintaining a robust pipeline of experimental therapies across various therapeutic areas.

Ask drillr about INCYTE CORP →

ValuationView details →

P/E (Fwd)

43.3x

P/E (TTM)

15.4x

EV/EBITDA

10.2x

EV/Sales

3.6x

P/S (TTM)

4.4x

P/B (TTM)

4.0x

ProfitabilityView details →

Gross Margin

92.62%

Net Margin

27.71%

EBITDA Margin

35.08%

ROE (TTM)

25.41%

ROA (TTM)

20.48%

Asset Turnover

0.77x

GrowthView details →

Revenue YoY

+26.93%

EPS YoY

+80.67%

FCF YoY

+103.10%

Revenue CAGR 3Y

+14.84%

EPS CAGR 3Y

+62.70%

EBITDA YoY

+50.62%

MomentumView details →

1D Return

−1.81%

YTD Return

+29.13%

1Y Return

+47.39%

RSI (14)

57.5

vs 50D SMA

+4.24%

vs 200D SMA

+20.72%

Capital & dividendView details →

Debt/Equity

0.01x

Current Ratio

4.66x

Quick Ratio

4.58x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

$3.09

EPS Surprise

43.72%

Beats (12Q)

8/12

Next Q EPS Est

−$2.83

Avg Surprise (4Q)

30.99%

Rev Surprise

11.31%

Financials snapshotView financials →

Revenue (TTM)

5.82B

Net Income (TTM)

1.61B

Op. CF (TTM)

1.98B

Next earningsOct 27, 2026 →

Latest newsMore news →

Whitehawk Therapeutics appointed Vijay Iyengar as a Class III director effective September 9, 2026, with an initial stock option award for 76,080 shares.10d ago

Oruka Therapeutics, Inc. appointed Todd Edwards as Chief Commercial Officer, effective with a base salary of $525,000, a target bonus of 40% of annual base salary, a signing bonus of $200,000, and equity grants including a stock option for 20,000 shares and restricted stock units for 100,000 shares of Oruka common stock.28d ago

Similar companies

InnoCare Pharma Limited09969.HK Royalty Pharma plcRPRX Insmed IncorporatedINSM Biocytogen Pharmaceuticals (Beijing) Co., Ltd.02315.HK 特宝生物688278.SH BioNTech SEBNTX Find similar companies →

Latest newsMore news →

Whitehawk Therapeutics appointed Vijay Iyengar as a Class III director effective September 9, 2026, with an initial stock option award for 76,080 shares.10d ago Oruka Therapeutics, Inc. appointed Todd Edwards as Chief Commercial Officer, effective with a base salary of $525,000, a target bonus of 40% of annual base salary, a signing bonus of $200,000, and equity grants including a stock option for 20,000 shares and restricted stock units for 100,000 shares of Oruka common stock.28d ago Incyte's Opzelura (ruxolitinib) cream received EU approval as the first steroid-free topical JAK inhibitor for adults with moderate atopic dermatitis.53d ago